UNASSIGNED: The ONCOMINE, UALCAN, GEPIA, cBioPortal, FusionGDB, SurvivalMeth, and the Human Protein Atlas databases were searched for NTRK gene expression and protein data in LIHC. Immunohistochemistry was used to detect pan-Trk expression across a commercial microarray containing 96 hepatocellular carcinoma (HCC) and 94 para-cancerous tissue spots. A modified histological score (H-score) with a maximum score of 300 was used to quantify immunohistochemical staining for pan-Trk. Student\'s t- and chi-square tests were the main statistical analyses used.
UNASSIGNED: The transcriptional levels of NTRK genes in LIHC were not significantly different from healthy controls. Using UALCAN and GEPIA, only high expression of NTRK2 was significantly associated with longer disease-free survival (P = 0.004). The alteration frequencies were low (7% in NTRK1, 1.7% in NTRK2, and 2% in NTRK3). The methylation levels of NTRK genes were all significantly different as analyzed by UALCAN; the high-risk group displayed an unfavorable prognosis compared with the low-risk group for NTRK1 (P = 0.033) and NTRK3 (P = 0.005). The median H-score of pan-Trk in HCC and para-cancerous tissues was not statistically different (186.31 ± 23.86 and 192.38 ± 21.06, P = 0.065). No differences were observed in clinicopathological features of HCC with the median H-score for pan-Trk expression (p > 0.05). The survival rate of patients with pan-Trk expression was also not significantly different.
UNASSIGNED: The alteration frequency was low in NTRK genes, including gene fusion and methylation levels. Therefore, pan-Trk expression in HCC tissue has limited value in clinicopathological features and prognosis.
■ONCOMINE,UALCAN,GEPIA,cBioPortal,FusionGDB,SurvivalMeth,在LIHC中搜索NTRK基因表达和蛋白质数据。免疫组织化学用于检测包含96个肝细胞癌(HCC)和94个癌旁组织斑点的商业微阵列中的pan-Trk表达。使用最大评分为300的改良组织学评分(H评分)来定量pan-Trk的免疫组织化学染色。学生t检验和卡方检验是使用的主要统计分析。
■LIHC中NTRK基因的转录水平与健康对照没有显着差异。使用UALCAN和GEPIA,只有NTRK2的高表达与更长的无病生存期显著相关(P=0.004)。改变频率较低(NTRK1为7%,NTRK2为1.7%,NTRK3为2%)。通过UALCAN分析,NTRK基因的甲基化水平均存在显着差异;与NTRK1(P=0.033)和NTRK3(P=0.005)的低危组相比,高危组的预后不良。pan-Trk在HCC和癌旁组织中的中位H评分无统计学差异(186.31±23.86和192.38±21.06,P=0.065)。HCC的临床病理特征与pan-Trk表达的中位数H评分无差异(p>0.05)。pan-Trk表达患者的存活率也无明显差别。
■NTRK基因的改变频率较低,包括基因融合和甲基化水平。因此,pan-Trk在HCC组织中的表达对临床病理特征和预后的影响有限。